Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB-MSC for Peripheral Arterial Disease
NCT02287831Phase 2Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2014
- Primary completion
- Dec 2022
- Modality
- Stem Cell Therapies
01
Overview
Phase 2, open-label, single-arm trial of human umbilical cord mesenchymal stem cells in Peripheral Arterial Disease (PAD), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Safety and tolerability related to the intramuscular injection of autologous Umbilical cord blood derived stem cells at 6 months. Started Feb 2014; status: completed.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT02287831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02287831.